drugset / Trial / NCT04223752
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).
Timeline
- Start
- 2020-04-17
- Primary completion
- 2024-09-14
- Completion
- 2024-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceftolozane | Small molecule | 40 mg/kg | Intravenous |
| Subject | Ceftolozane | Small molecule | 2 g | Intravenous |
| Subject | Tazobactam | Small molecule | 20 mg/kg | Intravenous |
| Subject | Tazobactam | Small molecule | 1 g | Intravenous |